We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14
Avg Time Held
3.5
quarters
Top 10 Avg Time Held
3.5
quarters
Top 20 Avg Time Held
3.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.27% |
| 2 | Miscellaneous | 12.42% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Caris Life Sciences
CAI
$8.85B
| $143M | 4.78% |
8,009,447
+193,305
| +2% | +$4.23M |
2025 Q2
3 quarters
|
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $85.9M | 2.87% |
652,121
-99,413
| -13% | -$13.2M |
2023 Q1
12 quarters
|
|
3
Glaukos
GKOS
$9.83B
| $82.2M | 2.74% |
763,505
-158,474
| -17% | -$17.8M |
2022 Q4
13 quarters
|
|
|
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
| $78.9M | 2.63% |
1,986,768
-201,552
| -9% | -$5.16M |
2025 Q4
1 quarter
|
|
5
Xenon Pharmaceuticals
XENE
$3.37B
| $77.8M | 2.6% |
1,338,452
-486,624
| -27% | -$22.4M |
2022 Q4
13 quarters
|
|
6
Dianthus Therapeutics
DNTH
$4.39B
| $75.5M | 2.52% |
899,364
-374,571
| -29% | -$21.7M |
2025 Q3
2 quarters
|
|
|
7
Edgewise Therapeutics
EWTX
$3.95B
| $73.9M | 2.47% |
2,347,583
-2,863,248
| -55% | -$82.6M |
2024 Q3
6 quarters
|
|
|
8
iRhythm Holdings
IRTC
$3.48B
| $72M | 2.4% |
610,192
+392,847
| +181% | +$56.7M |
2022 Q4
13 quarters
|
|
9
DELISTED
Nuvalent
NUVL
| $71.8M | 2.39% |
700,429
-120,977
| -15% | -$12.3M |
2024 Q4
5 quarters
|
|
10
Kodiak Sciences
KOD
$5.59B
| $69.3M | 2.31% |
1,818,665
-254,123
| -12% | -$6.57M |
2025 Q4
1 quarter
|
|
|
11
CG Oncology
CGON
$5.58B
| $66.7M | 2.22% |
984,783
-885,788
| -47% | -$50.2M |
2024 Q1
8 quarters
|
|
|
12
argenx
ARGX
$52.2B
| $62M | 2.07% |
84,939
+53,932
| +174% | +$42.2M |
2023 Q4
9 quarters
|
|
13
Hinge Health
HNGE
$8.48B
| $56.1M | 1.87% |
1,455,123
+150,500
| +12% | +$6.25M |
2025 Q3
2 quarters
|
|
14
Acadia Pharmaceuticals
ACAD
$3.28B
| $55M | 1.84% |
2,471,199
+439,178
| +22% | +$10.5M |
2025 Q3
2 quarters
|
|
|
15
Monte Rosa Therapeutics
GLUE
$859M
| $52.7M | 1.76% |
3,206,574
+2,258,258
| +238% | +$43.2M |
2025 Q4
1 quarter
|
|
16
Krystal Biotech
KRYS
$9.73B
| $47.1M | 1.57% |
182,425
-19,676
| -10% | -$5.24M |
2022 Q4
13 quarters
|
|
17
Spyre Therapeutics
SYRE
$7.63B
| $47.1M | 1.57% |
932,823
-701,792
| -43% | -$26.5M |
2023 Q4
9 quarters
|
|
|
18
Guardant Health
GH
$22.3B
| $46.2M | 1.54% |
+499,712
| New | +$50.2M |
2026 Q1
0 quarters
|
|
19
Thermo Fisher Scientific
TMO
$250B
| $45.7M | 1.52% |
92,915
+12,190
| +15% | +$6.62M |
2024 Q4
5 quarters
|
|
|
20
Generate Biomedicines
GENB
$1.64B
| $44.9M | 1.5% |
+3,592,999
| New | +$43.9M |
2026 Q1
0 quarters
|
|
21
MBX Biosciences
MBX
$2.39B
| $44.6M | 1.49% |
1,492,467
+473,867
| +47% | +$16.1M |
2025 Q4
1 quarter
|
|
22
BrightSpring Health Services
BTSG
$12.5B
| $43.3M | 1.44% |
1,016,562
-179,224
| -15% | -$7.22M |
2025 Q4
1 quarter
|
|
23
Celldex Therapeutics
CLDX
$2.25B
| $43M | 1.43% |
1,356,082
-502,027
| -27% | -$13.7M |
2025 Q3
2 quarters
|
|
24
NeoGenomics
NEO
$2.18B
| $41.7M | 1.39% |
5,617,402
+984,601
| +21% | +$10.4M |
2025 Q3
2 quarters
|
|
25
DELISTED
Apogee Therapeutics
APGE
| $40.3M | 1.34% |
478,667
-96,400
| -17% | -$7M |
2023 Q3
10 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q1 2026 Portfolio in Review
As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.
- Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
- Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
- Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
- Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
- Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
- Braidwell opened 28 new positions and closed 14 in Q1 2026.
- Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.
Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.